Literature DB >> 30100662

Power, Ethics and Obligation.

Jonathan Adam Gelfond1, Elizabeth Heitman2, Brad H Pollock3, Craig H Klugman4.   

Abstract

Entities:  

Year:  2012        PMID： 30100662      PMCID： PMC6082657          DOI： 10.1002/sim.5578

Source DB:  PubMed          Journal:  Stat Med        ISSN： 0277-6715            Impact factor:   2.373


× No keyword cloud information.
  8 in total

1.  Invited commentary: ethics and sample size--another view.

Authors:  Ross Prentice
Journal:  Am J Epidemiol       Date:  2005-01-15       Impact factor: 4.897

2.  Re: "Ethics and sample size".

Authors:  Scott D Halpern; Jason H T Karlawish; Jesse A Berlin
Journal:  Am J Epidemiol       Date:  2005-06-22       Impact factor: 4.897

3.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

Authors:  Ganesh Suntharalingam; Meghan R Perry; Stephen Ward; Stephen J Brett; Andrew Castello-Cortes; Michael D Brunner; Nicki Panoskaltsis
Journal:  N Engl J Med       Date:  2006-08-14       Impact factor: 91.245

4.  Principles for the ethical analysis of clinical and translational research.

Authors:  Jonathan A L Gelfond; Elizabeth Heitman; Brad H Pollock; Craig M Klugman
Journal:  Stat Med       Date:  2011-07-12       Impact factor: 2.373

5.  Simple, defensible sample sizes based on cost efficiency.

Authors:  Peter Bacchetti; Charles E McCulloch; Mark R Segal
Journal:  Biometrics       Date:  2008-06       Impact factor: 2.571

6.  The Nuremberg Code: Hippocratic ethics and human rights.

Authors:  E Shuster
Journal:  Lancet       Date:  1998-03-28       Impact factor: 79.321

7.  Ethics and sample size.

Authors:  Peter Bacchetti; Leslie E Wolf; Mark R Segal; Charles E McCulloch
Journal:  Am J Epidemiol       Date:  2005-01-15       Impact factor: 4.897

8.  The continuing unethical conduct of underpowered clinical trials.

Authors:  Scott D Halpern; Jason H T Karlawish; Jesse A Berlin
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.